Cash infusion from Nestlé buoys ChromaDex as it works to get costs under control
A cash infusion from Nestle and an uptick in online consumer sales has buoyed ChromaDex as executives say the brand is on course to be in plus EBITDA territory by the end of fiscal 2022.
